600351.SH
亚宝药业
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 6.78
−1.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.2B | 2.2B | 2.7B | 2.9B | 2.7B |
| Cost of Revenue | 1.0B | 1.1B | 1.3B | 1.2B | 1.2B |
| Gross Profit | 1.2B | 1.2B | 1.4B | 1.7B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 114.1M | 117.3M | 139.5M | 118.3M | 130.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 235.8M | 246.1M | 259.1M | 265.9M | 267.2M |
| Selling & Marketing Expense | 443.5M | 451.8M | 661.9M | 971.7M | 897.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 823.6M | 846.2M | 1.1B | 1.4B | 1.3B |
| Cost and Expenses | 1.9B | 1.9B | 2.4B | 2.6B | 2.5B |
| Operating Income (EBIT) | 366.9M | 370.8M | 300.0M | 226.3M | 123.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 370.9M | 374.5M | 292.1M | 219.0M | 125.6M |
| Income Tax Expense | 70.1M | 74.6M | 68.2M | 39.1M | 21.0M |
| Bottom Line | |||||
| Net Income | 319.4M | 320.0M | 242.7M | 199.6M | 104.7M |
| Earnings from Cont. Ops | 300.8M | 299.9M | 223.9M | 179.9M | 104.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 319.4M | 320.0M | 242.7M | 199.6M | 104.7M |
| Per Share | |||||
| Basic EPS | CN¥0.46 | CN¥0.46 | CN¥0.34 | CN¥0.26 | CN¥0.14 |
| Diluted EPS | CN¥0.46 | — | — | — | — |
| Revenue Per Share | CN¥3.17 | CN¥3.22 | CN¥3.76 | CN¥3.79 | CN¥3.64 |
| Shares | |||||
| Basic Shares Outstanding | 692.2M | 695.7M | 713.8M | 767.6M | 747.5M |
| Diluted Shares Outstanding | 692.2M | 695.7M | 713.8M | 767.6M | 747.5M |
| Profitability Metrics | |||||
| EBITDA | — | 505.5M | 436.9M | 382.4M | 284.1M |
| D&A | — | 134.6M | 136.9M | 156.1M | 160.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026